Evidence map›Paper›PMID 38899330›Full record

ArticleWorld journal of gastroenterology2024

Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors.

Wei-Nung Liu, Ming-Shen Dai, Felicia Lin, Gen-Min Lin

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei-Nung LiuDepartment of Medicine, Tri-Service General Hospital, Taipei 114, Taiwan.
Ming-Shen DaiDivision of Hematology/Oncology, Department of Internal Medicine, National Defense Medical Center, Taipei 114, Taiwan.
Felicia LinCommunity Care, Minnesota Oncology, Minneapolis, MN 55404, United States.
Gen-Min LinDepartment of Medicine, Hualien Armed Forces General Hospital, Hualien City 970, Taiwan. farmer507@yahoo.com.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this editorial, we offer a summary of the risk associated with hepatitis B reactivation (HBVr) in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase (BTK) inhibitors, with insights derived from current studies. Furthermore, we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments. This framework is essential for identifying those at increased risk of HBVr, enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.

Indexed as

Agammaglobulinaemia Tyrosine KinaseHepatitis B virusProtein Kinase InhibitorsVirus ActivationAntiviral AgentsHematologic NeoplasmsHepatitis BHepatitis B, ChronicHumansRisk AssessmentTyrosine Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseAntiviral AgentsBTK protein, humanProtein Kinase InhibitorsTyrosine Kinase InhibitorsBruton tyrosine kinase inhibitorsHematologic malignanciesHepatitis B virus reactivationProphylaxis guidelinesSolid tumors

Identifiers

PMID38899330
PMCPMC11185301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.